KMT2A and acute myeloid leukemia: Besides, MMPs could be involved in cell displacement and vascular leakiness, recent studies have suggested MMP inhibition could be a promising complementary therapy to reduce AML growth and limit HSPC loss and BM vascular damage caused by MLL-AF9 and possibly other AML subtypes [20].